KPV

No study cited here has given KPV to a person. Every finding below comes from cell lines, mice or rabbits.

What earns KPV attention is a tidy piece of transport biology. It is three amino acids long, small enough to be carried by PepT1, a membrane transporter that moves short peptides into gut lining cells and that turns up in the colon during inflammatory bowel disease. In cell culture, KPV quieted the NF-kappaB inflammatory switch at nanomolar concentrations once inside the cell, and in two chemically induced colitis models in mice it lowered the markers of colon inflammation. It is a coherent story in rodents that has never been checked in humans.

KPV is the tripeptide lysine, proline, valine (Lys-Pro-Val). Those three residues are positions 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), the hormone's C-terminal end, which is why older papers call it alpha-MSH(11-13).

Being cut from alpha-MSH does not make it a miniature alpha-MSH. In the 2008 Dalmasso study, KPV did not raise cyclic AMP in cells carrying melanocortin receptors, which is the signal those receptors normally send, and alpha-MSH itself failed to reproduce KPV's effect in the same intestinal cells. The fragment appears to act through a separate route.

A Transporter, Not a Receptor

PepT1 is a carrier that pulls di- and tripeptides from digested protein into intestinal cells. It is normally expressed in the small intestine and induced in the colon during inflammatory bowel disease. Dalmasso and colleagues found that PepT1 moves KPV into Caco2-BBE cells, a human intestinal cell line, with a Km of about 160 micromolar, which they describe as among the lowest Km values reported for this transporter. Gly-Sar, the standard test substrate, sits at 1 millimolar or above. In Jurkat cells, a human T cell line, the Km was about 700 micromolar.

The dependence on PepT1 was tested directly rather than assumed. In HT29-Cl.19A colon cells, which lack PepT1, KPV left IL-1 beta driven NF-kappaB activity untouched. When those cells were engineered to express PepT1, KPV reduced it, and adding a competing PepT1 substrate, Gly-Leu, abolished the effect.

What Happens Inside the Cell

In Caco2-BBE cells stimulated with IL-1 beta, 10 nanomolar KPV lowered NF-kappaB reporter activity and reduced the breakdown of IkappaB-alpha, the protein that holds NF-kappaB in check. The authors report reduced MAP kinase activation and IL-8 output as well. In TNF-alpha stimulated Jurkat cells, KPV significantly reduced the roughly 5-fold rise in IL-8 messenger RNA. The cell lines are of human origin, but this is cell culture; no person was involved.

Mouse colitis is not human bowel disease. DSS and TNBS are chemical injuries inflicted on mice over days. Lower myeloperoxidase and cytokine messenger RNA in those colons show that KPV blunted an induced injury in a rodent. What it would do in a person with ulcerative colitis or Crohn's disease has never been tested.

Fewer colitis tumors is not cancer prevention. In Viennois, the tumor reduction appeared only where inflammation drove the cancer and only in mice with working PepT1. In the genetic APCMin/+ model, KPV lowered an inflammation marker and left tumor burden unchanged. Even within mice the effect was narrow.

The parent hormone's effects do not carry over. Alpha-MSH acts on melanocortin receptors. KPV produced no cyclic AMP signal through those receptors in the cells tested, so pigmentation or appetite effects attributed to alpha-MSH are not KPV effects.

Inflammation markers are not a gut barrier result. None of these studies measured intestinal permeability or tight junctions. They measured inflammatory signalling, neutrophil markers, tissue appearance, weight and tumors. A barrier repair claim attaches an outcome nobody measured.

KPV's safety in humans is unknown. FDA states it has not identified any human exposure data on drug products containing KPV administered via any route of administration, and that it lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans. The animal studies here were built to measure inflammation and tumors, not toxicity, so they cannot fill that gap.

The whole evidence base here is one careful mechanistic study, one follow-up, and one rabbit eye study. Both gut studies come from Didier Merlin's laboratory, so no independent group's colitis data sits among these sources.

What would move KPV forward is easy to name: a human study showing whether KPV reaches tissue intact, a safety study in people, and a controlled trial in a defined condition with a clinical endpoint. None of those exists here. For now KPV is best read as a demonstration, in mice and cultured cells, that a gut peptide transporter can carry a small anti-inflammatory molecule into exactly the cells that are inflamed.

Not tested in people. No source gave KPV to a human, and FDA has identified no human exposure data for KPV drug products by any route.

Not a melanocortin agonist in the cells studied. KPV did not raise cyclic AMP in Caco2-BBE or Jurkat cells, and alpha-MSH did not reproduce its anti-inflammatory effect there.

Not an approved drug, and not cleared by FDA's withdrawal or advisory process. FDA has not approved KPV, and it sits on neither the Category 1 nor the Category 2 list. It left FDA Category 2 on or about 2026-04-22 because the nominators withdrew the nomination, not because FDA resolved its safety concerns. Those concerns remain published. KPV was reviewed at the FDA Pharmacy Compounding Advisory Committee meeting of 23-24 July 2026, and FDA's briefing document proposed that KPV not be added to the 503A list. FDA has published the agenda, the roster, the voting questions and its own presentation slides, but no minutes, transcript or written vote tally, so no outcome is stated here. A committee recommendation is not an FDA decision and would not change any legal status in any case; rulemaking on the full record decides that.

Not permitted in tested sport. KPV is not named on the WADA Prohibited List, but it is captured by S0 (Non-Approved Substances), which prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use. No WADA or national anti-doping ruling names KPV specifically.

Not shown to prevent cancer. It reduced colitis-driven tumors in wild-type mice, lost that effect in PepT1 knockout mice, and did not reduce tumors in the genetic APCMin/+ model.

I find KPV genuinely interesting, and the reason is the experimental design. Dalmasso's group did not stop at showing an effect. They took the transporter away and the effect went with it, and the same laboratory repeated that logic in knockout mice eight years later. That is cleaner work than sits behind many compounds with a far bigger following.

Clean mouse work is still mouse work, though. Nobody has measured what happens when a person takes KPV, whether it survives long enough to reach the colon, or what it does elsewhere along the way, and FDA says plainly that it has no human exposure data. So I am happy to use KPV to explain how gut inflammation is wired, and I will not tell anyone it does something for them, because nobody knows.